Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03739099
Other study ID # UF 7580
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 5, 2018
Est. completion date May 5, 2023

Study information

Verified date December 2021
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a randomized trial preceded by a run-in period and followed by a non-randomized study extension. After 3 weeks of outpatient use of study pump (1 week) and study pump+CGM (2weeks) as run-in period, patient and parents will be admitted for 4-hour training to closed-loop (AP) mode. Following randomization (1:1), patient will be allocated to '24-hour' use of AP or 'dinner and overnight AP mode/day time pump and CGM use' for the next 18-week period. At 18-week visit, a study extension for a further 18-week period will be initiated. AP mode that will be prescribed to all patients will depend from an independent DSMB decision based upon study safety data collected after 6 and 12 weeks from the first 30 included patients. Visits will occur at week 27 (safety follow-up) and 36 (final visit).


Description:

The study is a randomized trial preceded by a run-in period and followed by a non-randomized study extension. After 3 weeks of outpatient use of study pump (1 week) and study pump+CGM (2weeks) as run-in period, patient and parents will be admitted for 4-hour training to closed-loop (AP) mode. Following randomization (1:1), patient will be allocated to '24-hour' use of AP or 'dinner and overnight AP mode/day time pump and CGM use' for the next 18-week period. A hotline phone number will be given to the patient and parents so that they can contact the study staff as needed. A logbook will be provided to collect details about hypoglycemic and hyperglycemic episodes, physical activity and noticeable events. Phone calls will be scheduled between investigator and patient+parents 48 hours, 1 week and 2 weeks after AP mode initiation. Potential misbehaviors will be corrected and all questions answered. If needed, AP parameters may be revised and reconfigured. Hospital visits will be scheduled 6, 12 and 18 weeks after AP mode initiation for the same purposes, plus HbA1c measurement at week 12 and 18. At 18-week visit, a study extension for a further 18-week period will be initiated. AP mode that will be prescribed to all patients will depend from an independent DSMB decision based upon study safety data collected after 6 and 12 weeks from the first 30 included patients. Visits will occur at week 27 (safety follow-up) and 36 (final visit).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 122
Est. completion date May 5, 2023
Est. primary completion date September 5, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 12 Years
Eligibility Inclusion Criteria: - Treatment of diabetes by insulin pump since > 6 months - HbA1c level < 10% Exclusion Criteria: - Unwillingness of one parent or the legally responsible party to participate in insulin treatment - Any associated chronic disease or therapy (except insulin) affecting glucose metabolism

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions
Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data

Locations

Country Name City State
France Montpellier University Hospital Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of time spent in the 70-180 mg/dl glucose range assessed on daily CGM data % time blood glucose in 70-180 mg/dl range 18 weeks
Secondary Percent of time spent with glucose level < 70, 60 and 50 mg/dl, assessed on daily CGM data Percent time while blood glucose is kept in safe 70-180 mg/dl range 18 and 36 weeks
Secondary Percent of time spent with glucose level > 180 and 300 mg/dl, assessed on daily CGM data Percent time while blood glucose is kept in safe 70-180 mg/dl range 18 and 36 weeks
Secondary Percent of time spent in the 70-140 mg/dl glucose range assessed on daily CGM data Percent time while blood glucose is kept in safe 70-180 mg/dl range 18 and 36 weeks
Secondary Mean glucose level assessed on daily CGM data CGM data will be used to calculate daily glucose mean to assess the efficacy of the algorithm on glucose control. 18 and 36 weeks
Secondary HbA1c level measured at week 12, 18, 27 and 36 Levels of glycated hemoglobin will be measured at different time intervals to assess the clinical impact of the use of the algorithm on patient diabetes. 12,18, 27 and 36 weeks
Secondary Number of needed interventions by the patients or care providers to treat hypoglycemia A logbook will be used all along the study by patients to record carbs intake in case of hypoglycemia. If patient required further assistance, care provider who will record third parties intervention. 18 and 36 weeks
Secondary Percent of time with AP functional, discriminating between each component failure modes Percent time while blood glucose is kept in safe 70-180 mg/dl range 18 and 36 weeks
Secondary Score of the Artificial Pancreas Acceptance Questionnaire This questionnaire consists of 15 affirmations about the use of AP and patient can answer in a scale from 0 (do not agree) to 6 (totally agree). The global score is calculated by the sum of all answers. A high score means a good acceptation of the system. There is no subscale. 18 and 36 weeks